Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb placebo-controlled trial of inhaled EXO-CD24 in adults with mild to moderate ARDS
MOH_2021-06-17_010053Phase 2Completed
- Sponsor
- Nano24
- Start
- May 2021
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing EXO-CD24 with Placebo saline (2 arms). Primary endpoint: Primary endpoint not reported. Started May 2021; status: completed.
02
Drugs
exosomes overexpressing CD24
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on MOH_2021-06-17_010053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-06-17_010053.